A gaseous way to keep cardiac diseases at bay: Hydrogen gas-based cardiac rejuvenation therapy: Inhalation  or Subcutaneous injection of hydrogen gas suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy, via up regulation of its target gene, 22/March/2019, 8.40 am

Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA LINC00319 augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM, via upregulation of its target gene, 22/March/2019, 8.23 am
March 22, 2019
Ethyl pyruvate-based therapy for diabetes:  Ethyl pyruvate decreases DNA-PPK expression, suppresses phosphorylation of HSP90a, increases AMPK activity, augments mitochondrial biogenesis and energy metabolism, promotes weight loss and exercise endurance and alleviates TIIDM, via down-regulation of its target gene, 22/March/2019, 8.55 am
March 22, 2019
Show all

What we say:

Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: A gaseous way to keep cardiac diseases at bay: Hydrogen gas-based cardiac rejuvenation therapy: Inhalation  or Subcutaneous injection of hydrogen gas suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy, via up regulation of its target gene


From the Significance of the study to Public health relevance:

Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) Dilated cardiomyopathy is the leading cause of Heart failure; (3) the raise  of death rate, due to cardiovascular disease, has increased from 12.3 million in 1990 to 17.3 million in 2013; (4) 13% of cardiovascular disease occur due to  uncontrolled high blood pressure; (5) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (6) 85% of people over  80 years are susceptible to cardiovascular diseases; (7) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (8) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; and (9) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find:  (i) a cure to diseases, as mentioned above, leading to cardiovascular disease; (ii) a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (iii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


From research findings to therapeutic opportunity:  

This study suggests, for the first time, a molecular hydrogen-based therapy for prevention of  dilated cardiomyopathy and heart failure. Subcutaneous injection or inhalation of Hydrogen gas (2%), by increasing the expression of its target gene, it may increase the expression of oncoprotein BMI-1 and suppress the expression of tumor suppressor  and the ageing marker INK4a/p16 (figure 1 ).

[easy_payment currency=”USD”]

Figure 1. Mechanistic insight into how Hydrogen gas (2%)  may function as a cardioprotective agent. Hydrogen gas inhibits dilated cardiomyopathy and heart failure via down regulation of ageing/senescence marker INK4a

Figure 2. Hydrogen gas (2%)  may attenuate senescence, and dilated cardiomyopathy through down regulation of INK4a.

Thereby, it may: (1) inhibit cardiac senescence; (2) increase of regenerative potential in aged tissues; and (3) improve ventricular dimensions and contractility. Together, (1) by making myocardial patients to undergo hydrogen gas-inhalation therapy, one may prevent dilated cardiomyopathy and ageing-associated (or, stress-associated) decline in cardiac function; and (2) hydrogen gas inhalation therapy, either alone or in combination with any other medical gas or compound,” may be used to treat dilated cardiomyopathy and heart failure (figure 1).


 

Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does subcutaneous injection or inhalation of Hydrogen gas (2%) decrease the expression of INK4a?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web: http://genomediscovery.org or newbioideas.com

Citation: Boominathan, L., A gaseous way to keep cardiac diseases at bay: Hydrogen gas-based cardiac rejuvenation therapy: Inhalation  or Subcutaneous injection of hydrogen gas suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy, via up regulation of its target gene, 22/March/2019, 8.40 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.